Ide-Cel's Benefit on PF Survival: Doris Hansen, MD
The hematologist from Moffitt Cancer Center discussed the survival benefit of ide-cel in the phase 2 KarMMa trial.
Identifying Patient-Specific Tumor Targets
Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the ATLAS platform and the TiTAN trial.
CAR T Therapies for Hematologic Malignancies and Solid Tumors
André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed therapies the company is developing.
Brexucabtagene Autoleucel's Impact on MCL Treatment Landscape: Luhua Wang, MD
The professor from The University of Texas MD Anderson Cancer discussed the impact that brexucabtagene autoleucel's approval has had on mantle cell lymphoma.
Current Limitations of CAR T-Cell Therapy in Multiple Myeloma: Muhamed Baljevic, MD
The assistant professor from University of Nebraska Medical Center discussed the current limitations of CAR T-cell therapy in multiple myeloma.
Advantages of mRNA-Based Gene Therapies
Jake Becraft, PhD, chief executive officer and cofounder, Strand Therapeutics, discussed the company’s technology and focus on mRNA therapies.
FDA Approval of Brexucabtagene Autoleucel for B-Cell ALL: Bijal Shah, MD, MS
The hematologist from Moffitt Cancer Center discussed the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.
Challenges With Conducting Clinical Trials in Gaucher Disease: Neil Weinreb, MD
The chair of the International Collaborative Gaucher Group Registry discussed challenges in Gaucher research.
NK Cell Therapy Potential in Treating COVID-19 and Other Viruses
Allen Feng, PhD, chief scientific officer, HebeCell, discussed the company’s NK cell technologies.
Unmet Needs and Management in Multiple Myeloma: Peter Voorhees, MD
The hematologist/oncologist discussed unmet needs and novel therapies in multiple myeloma and give practical advice for community oncologists.
Safety Concerns With Gene Therapies: Barry Byrne, MD, PhD
The director of the Powell Gene Therapy Center at the University of Florida discussed adverse events in gene therapies.
Regulating Cell and Gene Therapy Activity
Paul Wotton, PhD, chief executive officer, Obsidian Therapeutics, discussed the company’s pipeline and technologies.
Adverse Events in CAR T-Cell Therapies: Joseph A. Fraietta, PhD
The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed safety concerns with CAR T-cell therapies.
Challenges in Developing Gene Therapies for Gaucher Disease: Neil Weinreb, MD
The chair of the International Collaborative Gaucher Group Registry discussed the place of gene therapies in the Gaucher treatment landscape.
Future Research With Stem Cell Therapies in Hematologic Malignancies
The chief executive and chief medical officers of Vor Biopharma discussed the company’s future research and plans.
ASC Transplant Eligibility in Multiple Myeloma: Elisabet E. Manasanch, MD
The associate professor from The University of Texas MD Anderson Cancer Center discussed eligibility for autologous stem cell transplant in patients with multiple myeloma.
Exposing the Advantages of iPSC-Natural Killer Cell Therapies
Allen Feng, PhD, chief scientific officer, HebeCell, discussed advantages of induced pluripotent over hematopoietic stem cell therapies.
Cellular, Tissue, and Gene Therapies AdComm Meeting Takeaways: Barry Byrne, MD, PhD
The director of the Powell Gene Therapy Center at the University of Florida discussed the recent meeting of the FDA Cellular, Tissue, and Gene Therapies Advisory Committee.
Integrating TIL-Based Therapy into Melanoma Treatment: Omar Hamid, MD
The chief of translational Research and immunotherapy at The Angeles Clinic and Research Institute discussed the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.
KarMMA: Key Findings of Ide-Cel in Multiple Myeloma: Nina Shah, MD
The hematologist and oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed key findings from the phase 2 KarMMA trial.
Bolstering Stem Cells Against Off-Target Effects of Cancer Therapies
The chief executive and chief medical officers of Vor Biopharma discussed their focus on AML, CD33, and their lead program VOR33.
Developing Gene Therapies for AMD: Brandi L. Williams, PhD; Gregory S. Hageman, PhD
Directors from the Moran Eye Center discussed researching gene therapy approaches targeting HTRA1 in AMD.
Investigating BET Inhibitors to Improve CAR T Therapy: Joseph A. Fraietta, PhD
The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed JQ1 and other BET inhibitors he would like to study.
CAR T as Frontline Therapy for DLBC Lymphoma: Alex Herrera, MD
The hematologist/oncologist from City of Hope discussed the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.
Gene Therapy for Sickle Cell Disease
Experts discuss the safety profile and cost of gene therapy for the management of sickle cell disease.
Gene Therapy for Pompe Disease: Barry Byrne, MD, PhD
The director of the Powell Gene Therapy Center at the University of Florida discussed gene therapy programs being conducted for Pompe disease.
Challenges With CAR T Therapy in Multiple Myeloma: Larry D. Anderson Jr, MD, PhD
The associate professor from the UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center discussed the challenges faced with CAR T-cell therapy in patients with multiple myeloma.
Mitigating Cytokine Release Syndrome in CAR T for Multiple Myeloma: Krina K. Patel, MD, MSc
The associate professor from The University of Texas MD Anderson Cancer Center discussed mitigating CAR T-cell therapy–related cytokine release syndrome in multiple myeloma.
Reducing Off-Target Effects of CAR T-Cell Therapies
Eric von Hofe, PhD, president and chief operating officer of AffyImmune, discussed advantages of the Affinity tuning platform.
Targeting Cancers With CAR T and NK Cells
Jan Davidson, MD, PhD, chief medical officer, Wugen, discussed the company’s future plans and research.
